Bayer nets FDA’s priority review for cancer drug in U.S.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Pharmaceuticals, Biotechnology and Life Sciences
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…
Allergan has won FDA’s approval to sell its breast implants in US.
Sanofi has starts new year with big changes. In two separate statements the company announced closing a deal and ending a joint venture.
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
Shire has entered a new year with a new non-executive director, as it has appointed Ian Clark to the board. His new duties started immediately.
If you have problems with settling your stomach after having a nice meal, even if it had passed a couple of hours, you don’t want to jump to drugs immediately. Try these seven steps to reduce your abdominal pain.
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.